Relationship of amiodarone to postoperative complications of transthoracic implantation of automatic implantable cardioverter defibrillators

Hugh Calkins, M. Bahu, Y. Shyr, A. Schork, S. Bulling, W. Kou, M. Kirsch, F. Morady

Research output: Contribution to journalArticle

Abstract

The purpose of this study is to report the results and complications associated with transthoracic placement of an implantable defribillator and their relationship to amiodarone, and to identify clinical predictors of complications. There were 159 men and 41 women. The mean patients age was 61±11 years, and the mean ejection fraction was 0.33±0.14. Fifty one percent of patients developed complications including death in 14 patients (7%). Variables which differed in patients who died and those that did not were age, ejection fraction and New York heart failure classifications. Postoperative mortality was unrelated to amiodarone therapy. Twenty patients (10%) developed pneumonia and 15 patients (7.5%) developed respiratory failure. Clinical variables associated with the development of respiratory failure were age, amiodarone therapy and a prior history of pulmonary disease. Patients receiving amiodarone had a higher incidence of an elevated defibrillation threshold (≥25 joules) as compared with those not being treated with amiodarone. Clinical factors associated with an elevated defibrillation threshold were a history of a myocardial infarction, prior bypass surgery, and amiodarone. The results of this study demonstrate that placement of an implantable defibrillator using a transthoracic approach is associated with a high incidence of complications. Amiodarone therapy is associated with an increased incidence of pneumonia, respiratory failure, and elevated defibrillation thresholds.

Original languageEnglish (US)
Pages (from-to)89-97
Number of pages9
JournalPanminerva Medica
Volume38
Issue number2
StatePublished - 1996

Fingerprint

Amiodarone
Implantable Defibrillators
Respiratory Insufficiency
Incidence
Pneumonia
Lung Diseases
Therapeutics
Heart Failure
Myocardial Infarction
Mortality

Keywords

  • Amiodarone
  • Defibrillators, implantable
  • Postoperative complications

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Relationship of amiodarone to postoperative complications of transthoracic implantation of automatic implantable cardioverter defibrillators. / Calkins, Hugh; Bahu, M.; Shyr, Y.; Schork, A.; Bulling, S.; Kou, W.; Kirsch, M.; Morady, F.

In: Panminerva Medica, Vol. 38, No. 2, 1996, p. 89-97.

Research output: Contribution to journalArticle

Calkins, Hugh ; Bahu, M. ; Shyr, Y. ; Schork, A. ; Bulling, S. ; Kou, W. ; Kirsch, M. ; Morady, F. / Relationship of amiodarone to postoperative complications of transthoracic implantation of automatic implantable cardioverter defibrillators. In: Panminerva Medica. 1996 ; Vol. 38, No. 2. pp. 89-97.
@article{37045f847bf84314bdf78c491b9e500e,
title = "Relationship of amiodarone to postoperative complications of transthoracic implantation of automatic implantable cardioverter defibrillators",
abstract = "The purpose of this study is to report the results and complications associated with transthoracic placement of an implantable defribillator and their relationship to amiodarone, and to identify clinical predictors of complications. There were 159 men and 41 women. The mean patients age was 61±11 years, and the mean ejection fraction was 0.33±0.14. Fifty one percent of patients developed complications including death in 14 patients (7{\%}). Variables which differed in patients who died and those that did not were age, ejection fraction and New York heart failure classifications. Postoperative mortality was unrelated to amiodarone therapy. Twenty patients (10{\%}) developed pneumonia and 15 patients (7.5{\%}) developed respiratory failure. Clinical variables associated with the development of respiratory failure were age, amiodarone therapy and a prior history of pulmonary disease. Patients receiving amiodarone had a higher incidence of an elevated defibrillation threshold (≥25 joules) as compared with those not being treated with amiodarone. Clinical factors associated with an elevated defibrillation threshold were a history of a myocardial infarction, prior bypass surgery, and amiodarone. The results of this study demonstrate that placement of an implantable defibrillator using a transthoracic approach is associated with a high incidence of complications. Amiodarone therapy is associated with an increased incidence of pneumonia, respiratory failure, and elevated defibrillation thresholds.",
keywords = "Amiodarone, Defibrillators, implantable, Postoperative complications",
author = "Hugh Calkins and M. Bahu and Y. Shyr and A. Schork and S. Bulling and W. Kou and M. Kirsch and F. Morady",
year = "1996",
language = "English (US)",
volume = "38",
pages = "89--97",
journal = "Panminerva Medica",
issn = "0031-0808",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Relationship of amiodarone to postoperative complications of transthoracic implantation of automatic implantable cardioverter defibrillators

AU - Calkins, Hugh

AU - Bahu, M.

AU - Shyr, Y.

AU - Schork, A.

AU - Bulling, S.

AU - Kou, W.

AU - Kirsch, M.

AU - Morady, F.

PY - 1996

Y1 - 1996

N2 - The purpose of this study is to report the results and complications associated with transthoracic placement of an implantable defribillator and their relationship to amiodarone, and to identify clinical predictors of complications. There were 159 men and 41 women. The mean patients age was 61±11 years, and the mean ejection fraction was 0.33±0.14. Fifty one percent of patients developed complications including death in 14 patients (7%). Variables which differed in patients who died and those that did not were age, ejection fraction and New York heart failure classifications. Postoperative mortality was unrelated to amiodarone therapy. Twenty patients (10%) developed pneumonia and 15 patients (7.5%) developed respiratory failure. Clinical variables associated with the development of respiratory failure were age, amiodarone therapy and a prior history of pulmonary disease. Patients receiving amiodarone had a higher incidence of an elevated defibrillation threshold (≥25 joules) as compared with those not being treated with amiodarone. Clinical factors associated with an elevated defibrillation threshold were a history of a myocardial infarction, prior bypass surgery, and amiodarone. The results of this study demonstrate that placement of an implantable defibrillator using a transthoracic approach is associated with a high incidence of complications. Amiodarone therapy is associated with an increased incidence of pneumonia, respiratory failure, and elevated defibrillation thresholds.

AB - The purpose of this study is to report the results and complications associated with transthoracic placement of an implantable defribillator and their relationship to amiodarone, and to identify clinical predictors of complications. There were 159 men and 41 women. The mean patients age was 61±11 years, and the mean ejection fraction was 0.33±0.14. Fifty one percent of patients developed complications including death in 14 patients (7%). Variables which differed in patients who died and those that did not were age, ejection fraction and New York heart failure classifications. Postoperative mortality was unrelated to amiodarone therapy. Twenty patients (10%) developed pneumonia and 15 patients (7.5%) developed respiratory failure. Clinical variables associated with the development of respiratory failure were age, amiodarone therapy and a prior history of pulmonary disease. Patients receiving amiodarone had a higher incidence of an elevated defibrillation threshold (≥25 joules) as compared with those not being treated with amiodarone. Clinical factors associated with an elevated defibrillation threshold were a history of a myocardial infarction, prior bypass surgery, and amiodarone. The results of this study demonstrate that placement of an implantable defibrillator using a transthoracic approach is associated with a high incidence of complications. Amiodarone therapy is associated with an increased incidence of pneumonia, respiratory failure, and elevated defibrillation thresholds.

KW - Amiodarone

KW - Defibrillators, implantable

KW - Postoperative complications

UR - http://www.scopus.com/inward/record.url?scp=0030155807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030155807&partnerID=8YFLogxK

M3 - Article

C2 - 8979740

AN - SCOPUS:0030155807

VL - 38

SP - 89

EP - 97

JO - Panminerva Medica

JF - Panminerva Medica

SN - 0031-0808

IS - 2

ER -